References
- Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242: 233–246.
- Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68:974–982.
- Plotz SG, Wiesender M, Todorova A, et al. What is new in atopic dermatitis/eczema? Expert Opin Emerg Drugs. 2014;19: 441–458.
- Lio PA, Lee M, LeBovidge J, et al. Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012. J Allergy Clin Immunol Pract. 2014;2:361–369. quiz 370.
- Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13:549–561.
- Howell MD, Parker ML, Mustelin T, et al. Past, present, and future for biologic intervention in atopic dermatitis. Allergy. 2015;70:887–896.
- Weiss D, Schaschinger M, Ristl R, et al. Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2/22 expression. J Am Acad Dermatol. 2017;76:91–97.e3.
- Heratizadeh A, Werfel T. Anti-inflammatory therapies in atopic dermatitis. Allergy. 2016;71:1666–1675.
- Werfel T, Biedermann T. Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation. And Itch. Curr Opin Allergy Clin Immunol. 2015;15:446–452.
- SaekiKabashima H, Tokura KY, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol. 2017;177:419–427.
- Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28–35.
- Puya R, Alvarez-Lopez M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51:115–116.
- Fernandez-Anton Martinez MC, Alfageme Roldan F, Ciudad Blanco C, et al. Ustekinumab in the treatment of severe atopic dermatitis. a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105:312–313.
- Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 2015;1:25–26.
- Samorano LP, Hanifin JM, Simpson EL, et al. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol. 2016;30:522–523.
- Agusti-Mejias A, Messeguer F, Ramon G, et al. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 2013;25:368–370.
- Wlodek C, Hewitt H, Kennedy CT. Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol. 2016;41:625–627.
- Nic Dhonncha E, Clowry J, Dunphy M, et al. Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients. Br J Dermatol. 2017;177:1752–1753.